Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738582 · ClinicalTrials.gov registry record · Phase 2
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
A Phase 2 study, sponsored by Morphotek.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT00738582 is a Phase 2 study that has completed, run by Morphotek. The registered enrollment target is 89 participants.
The verdict
NCT00738582, a Phase 2 study, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG MORAb-009 (Amatuximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-12-31 |
| Est. Completion | 2014-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738582
The ClinicalTrials.gov registry entry for NCT00738582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00738582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00738582 about?
NCT00738582 is a clinical study titled "An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma". This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
What is the current status of trial NCT00738582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2008-12-31. Estimated completion is 2014-01-10.
What interventions are being tested in trial NCT00738582?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), MORAb-009 (Amatuximab) (DRUG).
Who is sponsoring clinical trial NCT00738582?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.